+Follow
KKYONG
No personal profile
4
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
KKYONG
2021-06-25
Great
HK-listed YiChang HEC rises most in 3 months on robust sales outlook
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":4087700861998360,"uuid":"4087700861998360","gmtCreate":1624597974066,"gmtModify":1624597974066,"name":"KKYONG","pinyin":"kkyong","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":122351503,"gmtCreate":1624599277202,"gmtModify":1703841427005,"author":{"id":"4087700861998360","authorId":"4087700861998360","authorIdStr":"4087700861998360","name":"KKYONG","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087700861998360"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122351503","repostId":"2146088024","repostType":4,"repost":{"id":"2146088024","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624598032,"share":"https://ttm.financial/m/news/2146088024?lang=&edition=fundamental","pubTime":"2021-06-25 13:13","market":"hk","language":"en","title":"HK-listed YiChang HEC rises most in 3 months on robust sales outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2146088024","media":"Reuters","summary":"** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the bigg","content":"<p>** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22</p>\n<p>** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse</p>\n<p>** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly</p>\n<p>** Says improved income structure will have a positive impact on future operating performance</p>\n<p>** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%</p>\n<p>** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%</p>\n<p>** By last close, the stock had fallen 18.9% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed YiChang HEC rises most in 3 months on robust sales outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed YiChang HEC rises most in 3 months on robust sales outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-25 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22</p>\n<p>** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse</p>\n<p>** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly</p>\n<p>** Says improved income structure will have a positive impact on future operating performance</p>\n<p>** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%</p>\n<p>** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%</p>\n<p>** By last close, the stock had fallen 18.9% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01558":"东阳光长江药业"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146088024","content_text":"** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22\n** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse\n** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly\n** Says improved income structure will have a positive impact on future operating performance\n** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%\n** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%\n** By last close, the stock had fallen 18.9% this year","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":122351503,"gmtCreate":1624599277202,"gmtModify":1703841427005,"author":{"id":"4087700861998360","authorId":"4087700861998360","authorIdStr":"4087700861998360","name":"KKYONG","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087700861998360"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122351503","repostId":"2146088024","repostType":4,"repost":{"id":"2146088024","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624598032,"share":"https://ttm.financial/m/news/2146088024?lang=&edition=fundamental","pubTime":"2021-06-25 13:13","market":"hk","language":"en","title":"HK-listed YiChang HEC rises most in 3 months on robust sales outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2146088024","media":"Reuters","summary":"** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the bigg","content":"<p>** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22</p>\n<p>** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse</p>\n<p>** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly</p>\n<p>** Says improved income structure will have a positive impact on future operating performance</p>\n<p>** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%</p>\n<p>** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%</p>\n<p>** By last close, the stock had fallen 18.9% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed YiChang HEC rises most in 3 months on robust sales outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed YiChang HEC rises most in 3 months on robust sales outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-25 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22</p>\n<p>** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse</p>\n<p>** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly</p>\n<p>** Says improved income structure will have a positive impact on future operating performance</p>\n<p>** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%</p>\n<p>** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%</p>\n<p>** By last close, the stock had fallen 18.9% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01558":"东阳光长江药业"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146088024","content_text":"** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd rise as much as 10.9% to HK$7.94, the biggest intraday percentage gain since March 22\n** Stock hits its highest since April 30; among the 30 biggest percentage gainers on the Hong Kong bourse\n** Company based in central province of Hubei says its newly acquired aripiprazole and rivaroxaban tablets won bid for centralised procurement, and sales volumes are set to increase significantly\n** Says improved income structure will have a positive impact on future operating performance\n** The Hong Kong Hang Seng Commerce & Industry Index rises 1.5%\n** The Hang Seng China Enterprises Index climbs 1.4% and the benchmark index gains 1.1%\n** By last close, the stock had fallen 18.9% this year","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
